Marielle MD - Daiichi Sankyo Global Devel

DSNKY Stock  USD 30.58  0.97  3.28%   

Insider

Marielle MD is Global Devel of Daiichi Sankyo Co
Phone81 3 6225 1111
Webhttps://www.daiichisankyo.com

Daiichi Sankyo Management Efficiency

The company has return on total asset (ROA) of 0.0209 % which means that it generated a profit of $0.0209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0432 %, meaning that it generated $0.0432 on every $100 dollars invested by stockholders. Daiichi Sankyo's management efficiency ratios could be used to measure how well Daiichi Sankyo manages its routine affairs as well as how well it operates its assets and liabilities.
Daiichi Sankyo Co has accumulated 143.07 B in total debt with debt to equity ratio (D/E) of 0.12, which may suggest the company is not taking enough advantage from borrowing. Daiichi Sankyo has a current ratio of 3.29, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Daiichi Sankyo until it has trouble settling it off, either with new capital or with free cash flow. So, Daiichi Sankyo's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Daiichi Sankyo sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Daiichi to invest in growth at high rates of return. When we think about Daiichi Sankyo's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Robert KowalskiNovartis AG ADR
53
Jennifer MauerMerck Company
N/A
Collette TaylorAstellas Pharma
60
Azita GerhardtAbbVie Inc
57
Montserrat LlamasGrifols SA ADR
59
Victor BultoNovartis AG ADR
46
Eva SchaeferJansenSanofi ADR
N/A
Chris SheldonAstraZeneca PLC ADR
N/A
MBA DVMAstraZeneca PLC ADR
65
Paul PenepentNovartis AG ADR
N/A
Risa LavizzoMoureyMerck Company
66
Dante BeccariaSanofi ADR
N/A
Dean LiMerck Company
58
Jannie OosthuizenMerck Company
53
A WashingtonJohnson Johnson
70
Maria LlanoGrifols SA ADR
59
BCH BMBristol Myers Squibb
57
Julie BrownGlaxoSmithKline PLC ADR
62
Gonzalo VinaAstraZeneca PLC ADR
N/A
William HaitJohnson Johnson
71
Josep CatllaSanofi ADR
N/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company was founded in 1899 and is headquartered in Tokyo, Japan. Daiichi Sankyo operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 16458 people. Daiichi Sankyo Co [DSNKY] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Daiichi Sankyo Leadership Team

Elected by the shareholders, the Daiichi Sankyo's board of directors comprises two types of representatives: Daiichi Sankyo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daiichi. The board's role is to monitor Daiichi Sankyo's management team and ensure that shareholders' interests are well served. Daiichi Sankyo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daiichi Sankyo's outside directors are responsible for providing unbiased perspectives on the board's policies.
Masahiko Ohtsuki, Executive Officer, Senior Director of Research in Main Research & Development Unit
Junichi Onuma, VP Department
Hiroyuki Okuzawa, Executive Officer and Presidentident of ASCA Company
Hideyuki Haruyama, Co Adviser
Akio Sakurai, Corp Unit
Yoshinori Kaneshima, Corp Unit
Kentaro Asakura, VP Department
Sunao DVM, Group Pres
Naoto Tsukaguchi, Corp Counsel
Takashi Matsumoto, Co HR
Marielle MD, Global Devel

Daiichi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Daiichi Sankyo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Daiichi Pink Sheet Analysis

When running Daiichi Sankyo's price analysis, check to measure Daiichi Sankyo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daiichi Sankyo is operating at the current time. Most of Daiichi Sankyo's value examination focuses on studying past and present price action to predict the probability of Daiichi Sankyo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daiichi Sankyo's price. Additionally, you may evaluate how the addition of Daiichi Sankyo to your portfolios can decrease your overall portfolio volatility.